UNASSIGNED: 79 Background: Following @entity1205 (D), treatment options for mCRPC include @entity15513 ( @entity8358 ), @entity15512 (AA), and @entity14164 . With the introduction of new agents, optimal sequencing is undefined. We evaluated the prevalence of sequencing of AA and @entity8358 following D in a large community-based cohort to develop a hypothesis for the most optimal sequence. METHODS: A retrospective analysis of treatment patterns using the MSH iKnowMed EHR was conducted. Post-D mCRPC @entity1 receiving @entity8358 and/or AA at full EHR sites with >= 2 visits were included; clinical trial @entity1 excluded. @entity8358 utilization between @entity1178 '10 and May'12 and sequencing of @entity8358 or/and AA from Apr'11 and May'12 (when both drugs were available) were examined. OS, time to treatment failure (TTF), and demographics analyses are ongoing. RESULTS: 667 evaluable @entity1 were identified. Overall @entity8358 (n=359 pts/2 y) utilization declined between @entity1178 '10-May'11 (n=232) and @entity1178 '11-May'12 (n=127). From Apr'11 to May'12: overall AA (n=465 pts/y) utilization increased between Mar-May'11 (n=73) to @entity1178 -Aug'11 (n=164) and subsequently decreased (n=57) from Mar-May'12. Between Apr'11-May'12, 130 @entity1 received both @entity8358 and AA. More @entity1 (P<0.001) received D > @entity8358 > AA (n=88, 67.7%) compared with D > AA > @entity8358 (n=42, 32.3%). Median age of @entity1 receiving both @entity8358 and AA was 67 (44-89) y and their median baseline PSA (111 evaluable) was 84.3 (0.4-7672.2) ng/mL. CONCLUSIONS: AA was administered more frequently than @entity8358 in post-D mCRPC @entity1 . However, the sequence of D > @entity8358 > AA was more prevalent than D > AA > @entity8358 in this large community-based cohort. Until predictive biomarkers and outcomes with respective sequences are identified, delivery of all active agents according to @entity1 -specific clinical factors should probably be considered. [Table: see text].

Sequencing of XXXX and @entity15512 following @entity1205 in metastatic castration-resistant prostate cancer (mCRPC).

@entity1 :: ('9606', 'Species') :: ['men', 'patients', 'patient'] @entity15512 :: ('MESH:C089742', 'Chemical') :: ['abiraterone acetate'] @entity14164 :: ('MESH:C540278', 'Chemical') :: ['enzalutamide'] @entity1178 :: ('3725', 'Gene') :: ['Jun'] @entity8358 :: ('D002220', 'Chemical') :: ['CBZ'] @entity15513 :: ('MESH:C552428', 'Chemical') :: ['cabazitaxel'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity15513 :: (MESH:C552428,Chemical) :: ['cabazitaxel']
